Shortness of Breath

Switched-off pulse oximeter beside a stethoscope
Vital signs and oxygen saturation are checked for fast breathing, low oxygen, low blood pressure and carbon dioxide retention.
Infographic: heart failure, asthma, lung clot and anemia
Common causes include heart failure, asthma, chronic obstructive pulmonary disease, pulmonary embolism, pneumonia and anemia.
3D air sacs: healthy, fluid-filled, then thickened and scarred
Impaired gas exchange, through ventilation-perfusion mismatch, shunt or diffusion impairment, is one of the mechanisms behind shortness of breath.

Table of Contents

  1. Overview
  2. Types of Dyspnea
  3. Common Causes
  4. Mechanisms
  5. Evaluation
  6. Management
  7. When to Seek Medical Care
  8. Connections
  9. Key Research Papers
  10. Featured Videos

Overview

Shortness of breath — or dyspnea — is the subjective experience of breathing discomfort. It is one of the most common reasons for ambulance calls and emergency room visits, and a frequent reason adults stop exercising before they realize anything is wrong with their heart or lungs. Like chest pain, dyspnea can mean almost anything — deconditioning, anemia, anxiety, asthma, heart failure, pulmonary embolism, interstitial lung disease (ILD), or cancer — and the workup is layered: a quick set of bedside vitals and an electrocardiogram (ECG) narrow it down at the bedside, with imaging and pulmonary function tests filling in the rest.

Types of Dyspnea

Common Causes

Mechanisms

Evaluation

Management

What the breathlessness studies found. The 2021 American Society of Clinical Oncology guideline on breathlessness in advanced cancer rests on a review of 48 randomized trials and two cohort studies. That review found that non-drug measures such as fans gave some relief and that support for drug treatments was limited. The guideline lists a fan directed at the cheek, standard oxygen for people with low blood oxygen, and self-management and breathing approaches as non-drug measures, and lists opioids for people who get too little relief from them. Low-dose morphine has been tested directly in chronic obstructive pulmonary disease: in the 2022 BEAMS trial at 20 centers in Australia, 160 people with severe chronic breathlessness were given 8 mg or 16 mg a day of extended-release morphine or a placebo. After one week, worst breathlessness was not significantly lower on either dose than on placebo (mean difference −0.3 points on a 0–10 scale for each dose), and the authors concluded that the findings do not support these doses for relieving breathlessness.

When to Seek Medical Care

Connections

Key Research Papers

Historical Background

The systematic taxonomy of dyspnea began with William Harvey's 17th-century circulation work and was refined by 20th-century physiologists. The Medical Research Council (MRC) dyspnea scale (1959) and the Borg scale (1982) standardized symptom reporting; cardiopulmonary exercise testing in the 1980s let clinicians separate ventilatory, cardiac, and gas-exchange limitations.

Key Research Papers

  1. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. American Journal of Respiratory and Critical Care Medicine. 2012;185(4):435-452. — doi:10.1164/rccm.201111-2042ST
  2. Mahler DA, O'Donnell DE. Recent advances in dyspnea. Chest. 2015;147(1):232-241. — doi:10.1378/chest.14-0800
  3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine. 2002;347(3):161-167. — doi:10.1056/NEJMoa020233
  4. Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. European Heart Journal. 2019;40(42):3453-3455. — PubMed PMID: 31697840
  5. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine. 2013;188(8):e13-e64. — PubMed PMID: 24127811
  6. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine. 2014;370(22):2071-2082. — doi:10.1056/nejmoa1402584
  7. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. Journal of Pain and Symptom Management. 2011;42(3):388-399. — PubMed PMID: 21458217
  8. Coccia CB, Palkowski GH, Schweitzer B, Motsohi T, Ntusi NA. Dyspnoea: pathophysiology and a clinical approach. South African Medical Journal. 2016;106(1):32-36. — PubMed PMID: 26933707
  9. Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of dyspnea. Deutsches Ärzteblatt International. 2016;113(49):834-845. — doi:10.3238/arztebl.2016.0834
  10. Banzett RB, Schwartzstein RM. Dyspnea: don't just look, ask! American Journal of Respiratory and Critical Care Medicine. 2015;192(12):1404-1406. — doi:10.1164/rccm.201508-1637ed
  11. Hui D, Bohlke K, Bao T, et al. Management of Dyspnea in Advanced Cancer: ASCO Guideline. Journal of Clinical Oncology. 2021;39(12):1389-1411. — PubMed PMID: 33617290
  12. Ekström M, Ferreira D, Chang S, et al. Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial. JAMA. 2022;328(20):2022-2032. — PubMed PMID: 36413230
  13. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2025;392(22):2193-2202. — PubMed PMID: 40387033

PubMed Topic Searches

  1. PubMed: Dyspnea evaluation
  2. PubMed: BNP and heart-failure diagnosis
  3. PubMed: Cardiopulmonary exercise testing for dyspnea
  4. PubMed: Pulmonary rehabilitation in COPD
  5. PubMed: Opioids for refractory dyspnea
  6. PubMed: Vocal-cord dysfunction

Back to Table of Contents

Shortness Of Breath — scientific infographic poster